(Albany, USA) DelveInsight’s “Inflammatory Bowel Disease Market Insights, Epidemiology, and Market Forecast-2034” report delivers an in-depth understanding of Inflammatory Bowel Disease, historical and forecasted epidemiology as well as the Inflammatory Bowel Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Inflammatory Bowel Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Inflammatory Bowel Disease market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Inflammatory Bowel Disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Inflammatory Bowel Disease market.
Request for a Free Sample Report @ Inflammatory Bowel Disease Market Forecast
Some facts of the Inflammatory Bowel Disease Market Report are:
- According to DelveInsight, Inflammatory Bowel Disease market size is expected to grow at a decent CAGR by 2034.
- Leading Inflammatory Bowel Disease companies working in the market are RedHill Biopharma, Celgene (Bristol Myers Squibb), Takeda Pharmaceutical, Janssen Pharmaceuticals, Hoffmann-La Roche, Genentech, AbbVie, Boehringer Ingelheim, Gilead Sciences, Arena Pharmaceuticals, Eli Lilly, AstraZeneca, and others.
- Key Inflammatory Bowel Disease Therapies expected to launch in the market are Etrasimod (APD334): Arena Pharmaceuticals/Pfizer, ABX464
- (obefazimod): Abivax , TREMFYA (guselkumab): Janssen (Johnson and Johnson) and others.
- In October 2023, the U.S. FDA approved OMVOH (mirikizumabmrkz) infusion (300 mg/15 mL)/injection (100 mg/mL), the first and only interleukin-23p19 (IL-23p19) antagonist for the treatment of moderately to severely active ulcerative colitis (UC) in adults.
- In May 2023, the U.S. FDA approved RINVOQ (upadacitinib) for the treatment of adults with moderately to severely active crohn’s disease (CD) who have had an inadequate response or intolerance to one or more TNF blockers.
- Over the last decade, the introduction of several key therapies has shaped the management of inflammatory bowel disease. Drugs like HUMIRA (adalimumab, AbbVie), REMICADE (infliximab, Janssen) and ENTYVIO (vedolizumab, Takeda) have helped patients achieve meaningful endpoints of clinical remission and mucosal healing.
Inflammatory Bowel Disease Overview
Inflammatory Bowel Disease (IBD) encompasses a group of chronic inflammatory conditions affecting the gastrointestinal tract, primarily the colon and small intestine. The two main types of Inflammatory Bowel Disease are Crohn’s disease and ulcerative colitis, both characterized by periods of inflammation and remission. Symptoms include abdominal pain, diarrhoea, rectal bleeding, weight loss, and fatigue, which can significantly impair quality of life. The exact cause of Inflammatory Bowel Disease remains unclear, but factors such as genetics, immune system dysfunction, environmental triggers, and alterations in gut micro biota are believed to play roles in its development. Inflammatory Bowel Disease Diagnosis typically involves a combination of medical history, physical examination, imaging tests, endoscopic procedures, and laboratory tests to rule out other conditions. Inflammatory Bowel Disease Treatment aims to control inflammation, alleviate symptoms, and achieve and maintain remission. This may involve medications such as anti-inflammatory drugs, immunosuppressant’s, biologics, and antibiotics, as well as lifestyle modifications and in severe cases, surgery to remove affected portions of the intestine. Management of Inflammatory Bowel Disease often requires a multidisciplinary approach involving gastroenterologists, nutritionists, mental health professionals, and support groups to address both the physical and emotional aspects of the disease.
Do you know what will be the Inflammatory Bowel Disease market share in 7MM by 2034 @ https://www.delveinsight.com/sample-request/inflammatory-bowel-disease-market
Inflammatory Bowel Disease Market
The Inflammatory Bowel Disease market has evolved significantly over the past decade, with therapies like HUMIRA, REMICADE, and ENTYVIO enabling clinical remission, mucosal healing, and reduced colectomy rates. Emerging treatments, including dual-targeted therapies and bispecific antibodies, offer hope for patients with refractory IBD by improving outcomes and quality of life.
The United States currently dominates the Inflammatory Bowel Disease market among the 7MM (seven major markets). The Inflammatory Bowel Disease market is expected to grow positively with the launch of novel therapies such as obefazimod, MORF-057, and tulisokibart. Opportunities remain in addressing the unmet needs of relapsed or refractory cases, particularly in the ulcerative colitis space.
Factors driving market growth include rising Inflammatory Bowel Disease prevalence, better diagnostic practices, an aging population, advancements in treatment, increased healthcare spending, and expanded access to healthcare services. The market is projected to expand significantly during the forecast period of 2024–2034.
The Inflammatory Bowel Disease market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Inflammatory Bowel Disease market trends by analyzing the impact of current Inflammatory Bowel Disease therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Inflammatory Bowel Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Inflammatory Bowel Disease market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Inflammatory Bowel Disease market in 7MM is expected to witness a major change in the study period 2020-2034.
Inflammatory Bowel Disease Epidemiology
The Inflammatory Bowel Disease epidemiology section provides insights into the historical and current Inflammatory Bowel Disease patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Inflammatory Bowel Disease market report also provides the diagnosed patient pool, trends, and assumptions.
- The US accounted for ~50% of the total Inflammatory Bowel Disease Diagnosed Prevalent Cases in the 7MM in 2023. These cases are expected to increase during the forecast period.
- In the US, the moderate to severe cases were found to be higher than the mild cases of Inflammatory Bowel Disease in 2023.
Interested to know how the emerging diagnostic approaches will be contributing in increased Inflammatory Bowel Disease diagnosed prevalence pool? Download report @ Inflammatory Bowel Disease Prevalence
Inflammatory Bowel Disease Drugs Uptake
This section focuses on the uptake rate of the potential Inflammatory Bowel Disease drugs recently launched in the Inflammatory Bowel Disease market or expected to be launched in 2020-2034. The analysis covers the Inflammatory Bowel Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Inflammatory Bowel Disease Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Inflammatory Bowel Disease market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Inflammatory Bowel Disease Pipeline Development Activities
The Inflammatory Bowel Disease report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Inflammatory Bowel Disease key players involved in developing targeted therapeutics.
Download report to know which TOP 3 therapies will be capturing the largest Inflammatory Bowel Disease market share by 2034? Click here @ Inflammatory Bowel Disease Treatment Market
Inflammatory Bowel Disease Therapeutics Assessment
Major key companies are working proactively in the Inflammatory Bowel Disease Therapeutics market to develop novel therapies which will drive the Inflammatory Bowel Disease treatment markets in the upcoming years are, RedHill Biopharma, Celgene (Bristol Myers Squibb), Takeda Pharmaceutical, Janssen Pharmaceuticals, Hoffmann-La Roche, Genentech, AbbVie, Boehringer Ingelheim, Gilead Sciences, Arena Pharmaceuticals, Eli Lilly, AstraZeneca, and others.
Do you know how Etrasimod (APD334) and TREMFYA (guselkumab) market launch will be impacting the Inflammatory Bowel Disease market CAGR? Download sample report @ Inflammatory Bowel Disease Drugs Market
Inflammatory Bowel Disease Report Key Insights
1. Inflammatory Bowel Disease Patient Population
2. Inflammatory Bowel Disease Market Size and Trends
3. Key Cross Competition in the Inflammatory Bowel Disease Market
4. Inflammatory Bowel Disease Market Dynamics (Key Drivers and Barriers)
5. Inflammatory Bowel Disease Market Opportunities
6. Inflammatory Bowel Disease Therapeutic Approaches
7. Inflammatory Bowel Disease Pipeline Analysis
8. Inflammatory Bowel Disease Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Inflammatory Bowel Disease Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Inflammatory Bowel Disease Competitive Intelligence Analysis
4. Inflammatory Bowel Disease Market Overview at a Glance
5. Inflammatory Bowel Disease Disease Background and Overview
6. Inflammatory Bowel Disease Patient Journey
7. Inflammatory Bowel Disease Epidemiology and Patient Population
8. Inflammatory Bowel Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Inflammatory Bowel Disease Unmet Needs
10. Key Endpoints of Inflammatory Bowel Disease Treatment
11. Inflammatory Bowel Disease Marketed Products
12. Inflammatory Bowel Disease Emerging Therapies
13. Inflammatory Bowel Disease Seven Major Market Analysis
14. Attribute Analysis
15. Inflammatory Bowel Disease Market Outlook (7 major markets)
16. Inflammatory Bowel Disease Access and Reimbursement Overview
17. KOL Views on the Inflammatory Bowel Disease Market
18. Inflammatory Bowel Disease Market Drivers
19. Inflammatory Bowel Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting